Form 4: Moderna President Hoge Reports Future Stock Transactions

Moderna President Stephen Hoge reported future acquisitions of common stock from RSU conversions and dispositions for tax withholding scheduled for late August 2025.

Summary

• Stephen Hoge, President of Moderna, Inc. (MRNA), reported future transactions involving company common stock.
• On August 27, 2025, Hoge is scheduled to acquire 1,437 shares of common stock upon the conversion of restricted stock units (RSUs).
• Concurrently on August 27, 2025, 695 shares of common stock are scheduled to be disposed of at a price of $24.73 to satisfy tax withholding obligations related to the RSU vesting.
• On August 28, 2025, Hoge is scheduled to acquire an additional 611 shares of common stock from RSU conversions.
• Also on August 28, 2025, 296 shares of common stock are scheduled to be disposed of at a price of $25.10 for tax withholding purposes.
• Following these transactions, Hoge's direct beneficial ownership will be 1,453,176 shares of common stock.
• Indirect beneficial ownership includes 4,116 shares held by Valhalla, LLC, and 151,933 shares held by a trust for the benefit of his spouse and children, for which Hoge disclaims Section 16 beneficial ownership except for pecuniary interest.

Sentiment

Score: 7

Explanation: The filing reports routine executive equity transactions, specifically the conversion of Restricted Stock Units (RSUs) into common stock and subsequent tax-related dispositions. This is an expected part of executive compensation and does not indicate any significant positive or negative operational or financial news for Moderna. The net effect is an increase in direct beneficial ownership for the executive.

Positives

• Acquisition of 1,437 shares and 611 shares of common stock through the conversion of Restricted Stock Units, indicating continued equity participation and alignment with shareholder interests.
• Continued vesting of RSU awards, with one award having 25% vested on February 27, 2025, and another on February 28, 2024, with remaining portions vesting quarterly, demonstrating ongoing long-term incentive compensation.

Negatives

• Disposition of 695 shares at $24.73 and 296 shares at $25.10 to cover tax withholding obligations, which reduces the net shares acquired from RSU vesting.

Future Outlook

The filing indicates future transactions for Stephen Hoge, President of Moderna, Inc., scheduled for August 27 and 28, 2025. These transactions involve the conversion of Restricted Stock Units (RSUs) into common stock and the subsequent disposition of shares to cover tax withholding obligations. The vesting schedules for the underlying RSU awards extend into the future, with remaining portions vesting in quarterly installments after initial vesting dates of February 27, 2025, and February 28, 2024.

Industry Context

This filing reflects routine executive compensation practices within the biotechnology and pharmaceutical industry, where Restricted Stock Units (RSUs) are a common component of long-term incentive plans. The conversion of RSUs into common stock and subsequent tax-related dispositions are standard procedures for executives receiving equity compensation.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of executive compensation is a standard practice across the biotechnology and pharmaceutical sectors, comparable to companies like Pfizer, BioNTech, and Johnson & Johnson, which also utilize equity awards to align executive interests with shareholder value.
• The disposition of shares to cover tax withholding obligations upon RSU vesting is a common and expected practice, consistent with how executives at peer companies manage their equity compensation.

Related Party Transactions

• Indirect ownership of 151,933 shares by a trust for the benefit of Dr. Hoge's spouse and children, with his spouse as a trustee. Dr. Hoge disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: The transactions reflect routine executive compensation and a slight increase in direct beneficial ownership by a key executive, which can be seen as aligning management's interests with shareholders.
• Employees: The RSU vesting demonstrates the company's long-term incentive programs for its executives, which are often mirrored in broader employee equity plans.

Next Steps

• Stephen Hoge will acquire 1,437 shares of common stock on August 27, 2025, and 611 shares on August 28, 2025, upon RSU conversion.
• Further quarterly installments of RSU awards will continue to vest based on the established schedules (after February 27, 2025, and February 28, 2024).

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events, specifically the vesting and conversion of Restricted Stock Units (RSUs) into common stock, followed by dispositions to cover tax obligations. Such transactions are standard and expected, reflecting the normal course of executive equity incentives. They do not provide new material information regarding Moderna's operational performance, strategic direction, or financial health that would warrant a change in investment thesis. Therefore, a "hold" recommendation is appropriate, as the filing confirms ongoing executive alignment through equity ownership without presenting new catalysts for a "buy" or "sell" decision.

Keywords

Moderna, MRNA, Stephen Hoge, insider trading, Form 4, stock transactions, RSU, restricted stock units, beneficial ownership, executive compensation, stock vesting, tax withholding